Who Paid My Doc
A Phase 1/2, Randomized, Observer-Blinded, Multi-Country Study to Eval
Research payments
$2,969,079
Through program year 2025, $2,969,079 in research payments was reported against A Phase 1/2, Randomized, Observer-Blinded, Multi-Country Study to Eval, across 616 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $153,409 | 61 |
| 2024 | Research | $343,076 | 107 |
| 2023 | Research | $1,807,070 | 375 |
| 2022 | Research | $665,524 | 73 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Cynthia Robbins Fort Worth, TX Named on 25 payments
- Muhammad Irfan Houston, TX Named on 24 payments
- Lisa Cohen Raleigh, NC Named on 21 payments
- Parke Hedges San Antonio, TX Named on 17 payments
- Aramis Cosme El Paso, TX Named on 13 payments
- Fabiana Farinetti Humble, TX Named on 13 payments
- Giselle Debs Perez North Miami Beach, FL Named on 12 payments
- Sooyeon Choi Dallas, TX Named on 11 payments
- Jorge Alvarez-Moreno Coral Gables, FL Named on 11 payments
- David Barker Chicago, IL Named on 11 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.